Thursday, July 28, 2016
Merck and AmoyDx collaborate to bring liquid biopsy RAS biomarker testing to China. Merck and AmoyDx plan to implement ADX-SuperARMS liquid biopsy RAS test in Chinese medical centers in 2017.
Plan to expand into other markets such as Argentina, India, Mexico, Taiwan, Hong Kong, Brazil, and Russia by 2019.
Test will be developed using AmoyDx real-time polymerase chain reaction technology,ADX-SuperARMS,will be made available in China in 2017.
Source : in.reuters.com
